Amphastar expands share buyback program
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Amphastar Pharmaceuticals Inc.'s board on Aug. 7 authorized an increase of $20.0 million to the company's share buyback program, which is expected to continue for an indefinite period of time.
The primary goal of the program is to offset dilution created by the company's equity compensation programs.
